Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
A phase 2 trial of Taletrectinib in non-small-cell lung cancer and small-cell lung cancer, run by Nuvation Bio Inc., active and no longer recruiting.
Overview
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC is a phase 2 interventional study registered as NCT04919811 by Nuvation Bio Inc., with 217 participants enrolled, started 2021-09-01 and due to reach its primary completion in 2025-06-11. Interventions recorded: Taletrectinib. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPhase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Shares Taletrectinib, Nuvation Bio, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Shares Taletrectinib, Nuvation Bio, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
Shares Nuvation Bio, Non-small-cell lung cancer.
- TargetROS1
Shares Taletrectinib, Non-small-cell lung cancer.